UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549



FORM 6-K


REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE MONTH OF MAY 2021


COMMISSION FILE NUMBER 001-38976

Genmab A/S
(Exact name of Registrant as specified in its charter)

Kalvebod Brygge 43

1560 Copenhagen V

Denmark

+45 70 20 27 28
(Address of principal executive offices)


Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F  Form 40-F 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1)

Yes  No 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7)

Yes  No 

This report on Form 6-K shall be deemed to be incorporated by reference in Genmab A/S’s registration statements on Form S-8 (File No. 333-232693) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

nthony

GENMAB A/S

BY:

/s/ Anthony Pagano

Name: Anthony Pagano

Title: Executive Vice President & Chief Financial Officer

DATE: May 3, 2021


EXHIBIT INDEX

O

Exhibit

Description of Exhibit

99.1

Company Announcement Dated May 3, 2021: Transactions in connection with share buy-back program

99.1(a)

Appendix: Transactions April 26-29, 2021


Exhibit 99.1

Graphic

Transactions in connection with share buy-back program

Company Announcement

COPENHAGEN, Denmark; May 3, 2021 – Genmab A/S (Nasdaq: GMAB). On February 23, 2021 Genmab announced the initiation of a share buy-back program to mitigate dilution from warrant exercises and to honor our commitments under our Restricted Stock Units program.

The share buy-back program is expected to be completed no later than June 30, 2021 and comprises up to 200,000 shares.

The following transactions were executed under the program from April 26, 2021 to April 30, 2021:

 

No. of shares

Average price (DKK)

Total value (DKK)

Accumulated through last announcement

122,900

 

255,207,568

April 26, 2021

1,400

2,206.24

3,173,268

April 27, 2021

1,500

2,217.64

3,428,445

April 28, 2021

April 29, 2021

1,500

1,600

2,233.89

2,281.41

3,393,795

3,661,392

April 30, 2021

0

N/A

0

Total

6,000

13,656,900

Accumulated under the program

128,900

 

268,864,468

Details of each transaction are included as an appendix to this announcement.

Following these transactions, Genmab holds 231,877 shares as treasury shares, corresponding to 0.35% of the total share capital and voting rights.

The share buy-back program is undertaken in accordance with Regulation (EU) No. 596/2014 (‘MAR’) and the Commission Delegated Regulation (EU) 2016/1052, also referred to as the “Safe Harbour Regulation.” Further details on the terms of the share buy-back program can be found in our company announcement no. 11 dated February 23, 2021.

About Genmab

Genmab is an international biotechnology company with a core purpose to improve the lives of patients with cancer. Founded in 1999, Genmab is the creator of multiple approved antibody therapeutics that are marketed by its partners. The company aims to create, develop and commercialize differentiated therapies by leveraging next-generation antibody technologies, expertise in antibody biology, translational research and data sciences and strategic partnerships. To create novel therapies, Genmab utilizes its next-generation antibody technologies, which are the result of its collaborative company culture and a deep passion for innovation. Genmab’s proprietary pipeline consists of modified antibody candidates, including bispecific T-cell engagers and next-generation immune checkpoint modulators, effector function enhanced antibodies and antibody-drug conjugates. The company is headquartered in Copenhagen, Denmark with locations in Utrecht, the Netherlands, Princeton, New Jersey, U.S. and Tokyo, Japan. For more information, please visit Genmab.com.

Genmab A/S

Tel: +45 7020 2728

Company Announcement no. 34

Kalvebod Brygge 43

Fax: +45 7020 2729

Page 1/2

21560 Copenhagen V, Denmark

www.genmab.com

CVR no. 2102 3884

LEI Code 529900MTJPDPE4MHJ122


Graphic

Transactions in connection with share buy-back program

Contact:
Marisol Peron, Senior Vice President, Global Investor Relations & Communications

T: +1 609 524 0065; E: mmp@genmab.com

For Investor Relations:

Andrew Carlsen, Vice President, Head of Investor Relations

T: +45 3377 9558; E: acn@genmab.com


This Company Announcement contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com and the risk factors included in Genmab’s most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.


Genmab A/S and/or its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo®; HuMax®; DuoBody®; DuoBody in combination with the DuoBody logo®; HexaBody®; HexaBody in combination with the HexaBody logo®; DuoHexaBody®; HexElect®; and UniBody®. Arzerra® and Kesimpta® are trademarks of Novartis AG or its affiliates. DARZALEX® and DARZALEX FASPRO® are trademarks of Janssen Pharmaceutica NV. TEPEZZA® is a trademark of Horizon Therapeutics plc.

Genmab A/S

Tel: +45 7020 2728

Company Announcement no. 34

Kalvebod Brygge 43

Fax: +45 7020 2729

Page 2/2

21560 Copenhagen V, Denmark

www.genmab.com

CVR no. 2102 3884

LEI Code 529900MTJPDPE4MHJ122


Exhibit 99.1(a)

APPENDIX Share buy-back programme - Specification for April 26-29, 2021

Graphic

Volume

Price

Venue

Time CET

20

2283

XCSE

20210429 9:00:22.541000

20

2290

XCSE

20210429 9:03:35.101000

4

2286

XCSE

20210429 9:06:28.471000

15

2286

XCSE

20210429 9:06:28.471000

21

2280

XCSE

20210429 9:11:16.388000

16

2280

XCSE

20210429 9:17:17.283000

2

2280

XCSE

20210429 9:17:17.289000

18

2280

XCSE

20210429 9:17:17.289000

42

2294

XCSE

20210429 9:28:21.045000

26

2300

XCSE

20210429 9:37:39.638000

19

2295

XCSE

20210429 9:44:16.217000

20

2300

XCSE

20210429 9:53:00.946000

19

2299

XCSE

20210429 10:01:45.982000

20

2299

XCSE

20210429 10:11:01.175000

19

2298

XCSE

20210429 10:21:51.656000

19

2296

XCSE

20210429 10:30:00.978000

20

2296

XCSE

20210429 10:42:42.670000

4

2296

XCSE

20210429 10:42:42.670000

19

2294

XCSE

20210429 10:55:52.745000

25

2294

XCSE

20210429 11:08:51.506000

19

2287

XCSE

20210429 11:19:54.116000

10

2285

XCSE

20210429 11:29:43.766709

30

2285

XCSE

20210429 11:29:43.766773

8

2285

XCSE

20210429 11:29:43.772492

2

2285

XCSE

20210429 11:29:43.784077

19

2282

XCSE

20210429 11:30:19.746000

20

2282

XCSE

20210429 11:30:19.746801

19

2282

XCSE

20210429 11:30:19.746831

30

2282

XCSE

20210429 11:30:19.746834

30

2282

XCSE

20210429 11:30:19.746835

1

2282

XCSE

20210429 11:30:19.746837

20

2285

XCSE

20210429 11:42:54.156000

21

2290

XCSE

20210429 12:00:16.762000

19

2287

XCSE

20210429 12:15:21.732000

19

2292

XCSE

20210429 12:28:55.516000

1

2291

XCSE

20210429 12:31:07.799000

19

2292

XCSE

20210429 12:45:28.852000

25

2291

XCSE

20210429 13:05:43.516000

20

2291

XCSE

20210429 13:05:43.516000

1


Exhibit 99.1(a)

APPENDIX Share buy-back programme - Specification for April 26-29, 2021

Graphic

20

2291

XCSE

20210429 13:17:23.647000

23

2294

XCSE

20210429 13:36:50.516000

23

2301

XCSE

20210429 13:37:50.554000

19

2294

XCSE

20210429 13:53:32.919000

7

2293

XCSE

20210429 14:09:05.163000

20

2293

XCSE

20210429 14:09:05.163000

25

2296

XCSE

20210429 14:17:03.635000

21

2301

XCSE

20210429 14:30:10.825000

19

2302

XCSE

20210429 14:33:04.808000

1

2298

XCSE

20210429 14:48:05.052000

21

2298

XCSE

20210429 14:48:05.052000

19

2297

XCSE

20210429 14:57:05.329000

19

2296

XCSE

20210429 14:58:44.677000

19

2291

XCSE

20210429 15:07:03.938000

54

2295

XCSE

20210429 15:24:48.892000

34

2295

XCSE

20210429 15:24:48.892000

21

2293

XCSE

20210429 15:26:53.710000

20

2294

XCSE

20210429 15:30:14.286000

4

2294

XCSE

20210429 15:30:14.286000

10

2294

XCSE

20210429 15:30:14.287000

6

2294

XCSE

20210429 15:30:19.951000

20

2282

XCSE

20210429 15:35:47.906000

19

2287

XCSE

20210429 15:41:16.889000

22

2286

XCSE

20210429 15:41:55.566000

20

2288

XCSE

20210429 15:47:15.575000

20

2279

XCSE

20210429 15:52:50.392000

19

2279

XCSE

20210429 15:52:50.392000

27

2285

XCSE

20210429 16:00:31.594000

19

2285

XCSE

20210429 16:06:30.059000

41

2285

XCSE

20210429 16:06:30.059000

1

2285

XCSE

20210429 16:06:30.059000

31

2287

XCSE

20210429 16:07:19.570000

19

2279

XCSE

20210429 16:13:03.797000

19

2278

XCSE

20210429 16:13:24.300000

20

2280

XCSE

20210429 16:21:14.002000

22

2280

XCSE

20210429 16:24:46.510000

10

2278

XCSE

20210429 16:33:02.378352

30

2278

XCSE

20210429 16:33:02.378362

30

2278

XCSE

20210429 16:33:02.378370

8

2278

XCSE

20210429 16:33:02.378470

2


Exhibit 99.1(a)

APPENDIX Share buy-back programme - Specification for April 26-29, 2021

Graphic

2

2278

XCSE

20210429 16:33:19.845972

19

2279

XCSE

20210429 16:34:16.738000

10

2278

XCSE

20210429 16:35:58.933071

3

2278

XCSE

20210429 16:35:58.933104

7

2278

XCSE

20210429 16:35:58.933288

2

2275

XCSE

20210429 16:38:11.181000

17

2275

XCSE

20210429 16:38:11.181000

17

2275

XCSE

20210429 16:43:02.991000

8

2275

XCSE

20210429 16:44:52.106000

13

2275

XCSE

20210429 16:44:52.371000

20

2240

XCSE

20210428 9:12:15.570000

19

2239

XCSE

20210428 9:16:42.307000

23

2227

XCSE

20210428 9:22:23.532000

21

2237

XCSE

20210428 9:27:26.177000

21

2246

XCSE

20210428 9:34:50.603000

19

2243

XCSE

20210428 9:41:33.413000

24

2244

XCSE

20210428 9:50:05.224000

19

2246

XCSE

20210428 9:56:35.020000

19

2252

XCSE

20210428 10:05:13.912000

22

2247

XCSE

20210428 10:17:41.293000

3

2247

XCSE

20210428 10:17:41.293000

11

2248

XCSE

20210428 10:27:42.530000

8

2248

XCSE

20210428 10:29:09.983000

16

2249

XCSE

20210428 10:35:01.086000

5

2249

XCSE

20210428 10:35:01.086000

22

2253

XCSE

20210428 10:48:11.034000

19

2252

XCSE

20210428 10:50:31.425000

19

2251

XCSE

20210428 11:02:14.198000

5

2254

XCSE

20210428 11:12:44.497000

14

2254

XCSE

20210428 11:12:44.497000

24

2251

XCSE

20210428 11:26:56.927000

19

2251

XCSE

20210428 11:35:33.360000

10

2248

XCSE

20210428 11:47:27.778000

9

2248

XCSE

20210428 11:47:27.778000

19

2248

XCSE

20210428 12:00:58.798000

15

2255

XCSE

20210428 12:14:09.303000

4

2255

XCSE

20210428 12:14:09.303000

14

2254

XCSE

20210428 12:27:23.662000

24

2257

XCSE

20210428 12:42:20.415000

16

2262

XCSE

20210428 12:55:56.495000

3


Exhibit 99.1(a)

APPENDIX Share buy-back programme - Specification for April 26-29, 2021

Graphic

4

2262

XCSE

20210428 12:55:56.495000

7

2261

XCSE

20210428 13:09:24.366000

12

2261

XCSE

20210428 13:09:24.366000

1

2259

XCSE

20210428 13:19:42.130000

19

2258

XCSE

20210428 13:22:32.213000

21

2255

XCSE

20210428 13:41:50.658000

19

2255

XCSE

20210428 13:45:08.967000

26

2263

XCSE

20210428 13:57:30.613000

19

2259

XCSE

20210428 14:11:52.200000

8

2260

XCSE

20210428 14:19:43.706000

10

2260

XCSE

20210428 14:20:07.655000

19

2260

XCSE

20210428 14:22:37.831000

19

2261

XCSE

20210428 14:32:08.820000

3

2260

XCSE

20210428 14:38:42.654000

16

2260

XCSE

20210428 14:41:04.380000

11

2260

XCSE

20210428 14:48:35.760000

14

2260

XCSE

20210428 14:49:17.875000

14

2260

XCSE

20210428 14:49:17.875000

7

2258

XCSE

20210428 14:59:07.062000

3

2258

XCSE

20210428 14:59:28.611000

4

2258

XCSE

20210428 14:59:28.611000

4

2258

XCSE

20210428 14:59:28.611000

10

2258

XCSE

20210428 14:59:29.718000

9

2258

XCSE

20210428 14:59:29.718000

1

2258

XCSE

20210428 14:59:29.718000

19

2261

XCSE

20210428 15:07:24.641000

20

2261

XCSE

20210428 15:07:24.641000

10

2263

XCSE

20210428 15:29:55.022000

22

2267

XCSE

20210428 15:30:17.693000

13

2267

XCSE

20210428 15:30:17.693000

54

2267

XCSE

20210428 15:30:17.693000

26

2267

XCSE

20210428 15:30:17.693000

30

2267

XCSE

20210428 15:30:17.693000

17

2267

XCSE

20210428 15:30:17.693000

20

2260

XCSE

20210428 15:35:29.259000

19

2259

XCSE

20210428 15:36:02.064000

3

2258

XCSE

20210428 15:40:13.312000

16

2258

XCSE

20210428 15:40:13.312000

28

2266

XCSE

20210428 15:44:03.239000

8

2268

XCSE

20210428 15:45:34.938000

4


Exhibit 99.1(a)

APPENDIX Share buy-back programme - Specification for April 26-29, 2021

Graphic

13

2268

XCSE

20210428 15:45:34.938000

20

2271

XCSE

20210428 15:50:35.279000

20

2271

XCSE

20210428 15:51:19.425000

10

2286

XCSE

20210428 15:59:01.218104

26

2287

XCSE

20210428 16:00:15.657000

10

2286

XCSE

20210428 16:00:15.710607

30

2286

XCSE

20210428 16:00:15.710658

21

2287

XCSE

20210428 16:10:17.983000

17

2281

XCSE

20210428 16:19:08.928000

3

2281

XCSE

20210428 16:19:08.928000

19

2280

XCSE

20210428 16:38:25.059000

20

2279

XCSE

20210428 16:50:48.780357

30

2279

XCSE

20210428 16:50:48.780381

30

2279

XCSE

20210428 16:50:48.780386

30

2279

XCSE

20210428 16:50:48.780388

30

2279

XCSE

20210428 16:50:48.780390

20

2279

XCSE

20210428 16:50:48.781886

80

2279

XCSE

20210428 16:50:48.781886

3

2279

XCSE

20210428 16:50:48.800972

21

2284

XCSE

20210427 9:00:23.527000

24

2285

XCSE

20210427 9:04:17.487000

19

2287

XCSE

20210427 9:08:20.277000

19

2290

XCSE

20210427 9:10:07.760000

19

2288

XCSE

20210427 9:13:57.790000

21

2289

XCSE

20210427 9:19:29.507000

25

2294

XCSE

20210427 9:26:05.736000

19

2294

XCSE

20210427 9:32:49.277000

19

2297

XCSE

20210427 9:39:14.572000

20

2313

XCSE

20210427 9:47:32.981000

19

2307

XCSE

20210427 9:55:11.881000

19

2302

XCSE

20210427 10:05:24.162000

1

2302

XCSE

20210427 10:05:24.162000

23

2301

XCSE

20210427 10:16:09.242000

1

2304

XCSE

20210427 10:21:53.806000

19

2305

XCSE

20210427 10:25:42.593000

19

2297

XCSE

20210427 10:36:06.317000

21

2302

XCSE

20210427 10:45:43.837000

19

2304

XCSE

20210427 10:50:26.956000

19

2306

XCSE

20210427 10:57:39.136000

34

2309

XCSE

20210427 11:18:44.283000

5


Exhibit 99.1(a)

APPENDIX Share buy-back programme - Specification for April 26-29, 2021

Graphic

19

2309

XCSE

20210427 11:25:24.062000

19

2307

XCSE

20210427 11:29:09.755000

19

2305

XCSE

20210427 11:39:09.501000

19

2302

XCSE

20210427 11:51:20.672000

19

2300

XCSE

20210427 11:55:04.653000

19

2299

XCSE

20210427 12:15:17.629000

26

2298

XCSE

20210427 12:26:47.734000

19

2297

XCSE

20210427 12:34:26.045000

11

2290

XCSE

20210427 12:52:38.366000

19

2290

XCSE

20210427 13:03:48.385000

31

2290

XCSE

20210427 13:10:42.213000

25

2287

XCSE

20210427 13:21:02.738000

26

2286

XCSE

20210427 13:22:22.711000

33

2282

XCSE

20210427 13:35:54.847000

37

2280

XCSE

20210427 13:46:25.229000

30

2281

XCSE

20210427 14:01:06.112000

7

2281

XCSE

20210427 14:01:06.112000

10

2281

XCSE

20210427 14:01:06.112000

42

2288

XCSE

20210427 14:24:07.806000

2

2284

XCSE

20210427 14:36:11.207000

53

2284

XCSE

20210427 14:46:28.781000

14

2284

XCSE

20210427 14:46:28.781000

48

2284

XCSE

20210427 14:46:28.781000

7

2280

XCSE

20210427 14:53:22.523000

35

2280

XCSE

20210427 14:53:22.523000

32

2277

XCSE

20210427 15:05:45.250000

15

2277

XCSE

20210427 15:05:45.250000

38

2276

XCSE

20210427 15:21:38.860000

10

2276

XCSE

20210427 15:21:38.860000

21

2271

XCSE

20210427 15:32:03.407000

20

2271

XCSE

20210427 15:32:03.407000

3

2271

XCSE

20210427 15:32:03.407000

50

2272

XCSE

20210427 15:43:03.162000

13

2265

XCSE

20210427 15:50:23.646000

22

2265

XCSE

20210427 15:50:23.646000

3

2266

XCSE

20210427 16:06:18.283000

40

2266

XCSE

20210427 16:06:18.284000

7

2266

XCSE

20210427 16:06:18.284000

37

2269

XCSE

20210427 16:14:04.152000

6

2269

XCSE

20210427 16:14:04.172000

6


Exhibit 99.1(a)

APPENDIX Share buy-back programme - Specification for April 26-29, 2021

Graphic

30

2273

XCSE

20210427 16:22:00.488000

17

2273

XCSE

20210427 16:22:00.488000

30

2271

XCSE

20210427 16:28:00.982000

5

2272

XCSE

20210427 16:28:00.982000

51

2275

XCSE

20210427 16:36:02.752000

21

2275

XCSE

20210427 16:38:08.128000

29

2275

XCSE

20210427 16:38:08.128000

1

2275

XCSE

20210427 16:38:08.128000

6

2275

XCSE

20210427 16:38:08.128000

4

2275

XCSE

20210427 16:38:08.128000

20

2261

XCSE

20210426 9:00:56.539000

25

2250

XCSE

20210426 9:04:43.625000

22

2267

XCSE

20210426 9:08:08.940000

20

2275

XCSE

20210426 9:11:21.630000

20

2274

XCSE

20210426 9:15:55.423000

19

2278

XCSE

20210426 9:21:01.968000

24

2278

XCSE

20210426 9:28:11.073000

19

2280

XCSE

20210426 9:35:25.830000

22

2282

XCSE

20210426 9:43:15.308000

19

2264

XCSE

20210426 9:51:50.965000

19

2264

XCSE

20210426 10:00:55.515000

21

2269

XCSE

20210426 10:12:07.143000

22

2264

XCSE

20210426 10:22:02.463000

19

2267

XCSE

20210426 10:31:13.205000

25

2267

XCSE

20210426 10:46:35.104000

19

2271

XCSE

20210426 10:55:27.586000

23

2275

XCSE

20210426 11:08:40.862000

18

2272

XCSE

20210426 11:21:04.329000

2

2272

XCSE

20210426 11:21:04.329000

19

2274

XCSE

20210426 11:33:27.850000

25

2269

XCSE

20210426 11:45:12.188000

43

2271

XCSE

20210426 12:17:21.647000

19

2270

XCSE

20210426 12:30:11.288000

19

2267

XCSE

20210426 12:46:09.910000

19

2265

XCSE

20210426 13:02:34.146000

10

2264

XCSE

20210426 13:02:34.166728

30

2264

XCSE

20210426 13:02:34.166770

10

2264

XCSE

20210426 13:02:34.166827

20

2265

XCSE

20210426 13:15:30.017000

1

2262

XCSE

20210426 13:29:54.865000

7


Exhibit 99.1(a)

APPENDIX Share buy-back programme - Specification for April 26-29, 2021

Graphic

22

2263

XCSE

20210426 13:37:13.194000

15

2268

XCSE

20210426 13:46:58.387000

4

2268

XCSE

20210426 13:46:58.387000

19

2270

XCSE

20210426 13:55:29.433000

19

2267

XCSE

20210426 14:03:27.302000

19

2266

XCSE

20210426 14:10:42.614000

19

2263

XCSE

20210426 14:17:53.600000

22

2257

XCSE

20210426 14:26:20.520000

6

2259

XCSE

20210426 14:32:02.925000

13

2259

XCSE

20210426 14:33:42.073000

19

2261

XCSE

20210426 14:36:56.607000

20

2263

XCSE

20210426 14:41:50.679000

19

2259

XCSE

20210426 14:47:19.521000

20

2265

XCSE

20210426 14:53:02.988000

21

2269

XCSE

20210426 14:59:03.657000

1

2266

XCSE

20210426 15:09:30.673000

25

2266

XCSE

20210426 15:09:30.673000

33

2270

XCSE

20210426 15:23:34.442000

17

2270

XCSE

20210426 15:23:34.442000

28

2270

XCSE

20210426 15:23:34.442000

26

2269

XCSE

20210426 15:24:13.850000

23

2271

XCSE

20210426 15:28:00.244000

19

2269

XCSE

20210426 15:28:34.808000

21

2272

XCSE

20210426 15:30:46.315000

21

2265

XCSE

20210426 15:33:42.705000

19

2260

XCSE

20210426 15:35:51.084000

9

2258

XCSE

20210426 15:38:49.725000

9

2258

XCSE

20210426 15:38:49.725000

10

2258

XCSE

20210426 15:41:15.547000

10

2258

XCSE

20210426 15:41:15.547000

15

2256

XCSE

20210426 15:44:11.914000

14

2254

XCSE

20210426 15:46:50.749000

19

2257

XCSE

20210426 15:50:06.208000

19

2255

XCSE

20210426 15:51:29.139000

20

2259

XCSE

20210426 15:54:22.351000

29

2261

XCSE

20210426 15:59:04.821000

29

2264

XCSE

20210426 16:04:53.072000

31

2264

XCSE

20210426 16:11:26.050000

20

2265

XCSE

20210426 16:16:28.037000

19

2269

XCSE

20210426 16:20:56.887000

8


Exhibit 99.1(a)

APPENDIX Share buy-back programme - Specification for April 26-29, 2021

Graphic

19

2270

XCSE

20210426 16:27:30.567000

5

2270

XCSE

20210426 16:38:53.313000

5

2275

XCSE

20210426 16:40:52.925279

21

2275

XCSE

20210426 16:40:52.925279

14

2275

XCSE

20210426 16:40:52.925279

9